Oryzon Genomics (BME: ORY)

Last close As at 26/12/2025

EUR3.18

0.00 (−0.16%)

Market capitalisation

EUR255m

Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. Central nervous system (CNS) asset vafidemstat has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder, and is in a Phase IIb trial for schizophrenia.

Latest Insights

View More

Healthcare | Comment

Oryzon (BME: ORY) strengthens iadademstat patent portfolio

Healthcare | Flash

Oryzon Genomics — ASH 2025: Promising iadademstat updates

Healthcare | Update

Oryzon Genomics — Progression across the pipeline in Q3

testalize-me-0jE8ynV4mis-unsplash

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Carlos Buesa

    CEO

Further insights

insight

Epigenetics

Thematics